Literature DB >> 26461007

Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis.

Sahaja Acharya1, Stephanie M Perkins1, Todd DeWees1, Benjamin W Fischer-Valuck1, David G Mutch2, Matthew A Powell2, Julie K Schwarz1, Perry W Grigsby3.   

Abstract

PURPOSE: To assess the use of brachytherapy (BT) with or without external beam radiation (EBRT) in inoperable stage I endometrial adenocarcinoma in the United States and to determine the effect of BT on overall survival (OS) and cause-specific survival (CSS). METHODS AND MATERIALS: Data between 1998 and 2011 from the National Cancer Institute's Surveillance, Epidemiology and End Results database were analyzed. Coarsened exact matching was used to adjust for differences in age and grade between patients who received BT and those who did not. Prognostic factors affecting OS and CSS were evaluated using the Kaplan-Meier product-limit method and a Cox proportional hazards regression model.
RESULTS: A total of 460 patients with inoperable stage I endometrial adenocarcinoma treated with radiation therapy were identified. Radiation consisted of either EBRT (n=260) or BT with or without EBRT (n=200). The only factor associated with BT use was younger patient age (median age, 72 vs 76 years, P=.001). Patients who received BT had a higher 3-year OS (60% vs 47%, P<.001) and CSS (82% vs 74%, P=.032) compared with those who did not. On multivariate analysis, BT use was independently associated with an improved OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.52-0.87) and CSS (HR 0.61, 95% CI 0.39-0.93). When patients were matched on age, BT use remained significant on multivariate analysis for OS (HR 0.65, 95% CI 0.48-0.87) and CSS (HR 0.52, 95% CI 0.31-0.84). When matched on age and grade, BT remained independently associated with improved OS and CSS (OS HR 0.62, 95% CI 0.46-0.83; CSS HR 0.57, 95% CI 0.34-0.92).
CONCLUSION: Brachytherapy is independently associated with improved OS and CSS. It should be considered as part of the treatment regimen for stage I inoperable endometrial cancer patients undergoing radiation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26461007     DOI: 10.1016/j.ijrobp.2015.06.013

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

2.  Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer.

Authors:  Lorena Draghini; Ernesto Maranzano; Michelina Casale; Fabio Trippa; Paola Anselmo; Fabio Arcidiacono; Stefania Fabiani; Marco Italiani; Luigia Chirico; Marco Muti
Journal:  J Contemp Brachytherapy       Date:  2017-04-27

3.  CT-Guided Pelvic Lymph Nodal Brachytherapy.

Authors:  Hiroaki Kunogi; I-Chow Hsu; Nanae Yamaguchi; Soshi Kusunoki; Keiko Nakagawa; Yayoi Sugimori; Kazunari Fujino; Yasuhisa Terao; Daiki Ogishima; Ryoichi Yoshimura; Keisuke Sasai
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

4.  Attitude and practice of brachytherapy in India: a study based on the survey amongst attendees of Annual Meeting of Indian Brachytherapy Society.

Authors:  Ajeet Kumar Gandhi; Daya Nand Sharma; Pramod Kumar Julka; Goura Kishor Rath
Journal:  J Contemp Brachytherapy       Date:  2015-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.